Sandbox Reserved 1783: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Template:CH462_Biochemistry_II_2023}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Template:CH462_Biochemistry_II_2023}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
== Sodium Taurocholate Co-Transporting Peptide == | === Sodium Taurocholate Co-Transporting Peptide === | ||
<StructureSection load='7zyi' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='7zyi' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| Line 48: | Line 48: | ||
=== HBV/HDV === | === HBV/HDV === | ||
<scene name='95/952711/Pres1_binding_area_on_ntcp/2'>PreS1 Binding</scene> | <scene name='95/952711/Pres1_binding_area_on_ntcp/2'>PreS1 Binding</scene> | ||
Hepatitis B and D both rely on NTCP to bind and infect a human. HBV/HDV uses a similar mechanism as bile salt uptake within NTCP. The myristoylated (myr) pre-S1 domain of HBV is critical for its binding within the protein. Residues 8-17 within the pre-S1 domain were found to be most important in pre-S1 binding to NTCP. HBV/HDV uses the binding patches on the outside of the protein to successfully bind. HBV/HDV binding halts the uptake of bile salt, indicating that the tunnel formed within NTCP allows the uptake of bile salts may also mediate the binding of HBV/HDV[[Media:https://www.nature.com/articles/s41586-022-04845-4]] | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
